March 7th 2024
Tocilizumab-aazg (Tyenne; Fresenius Kabi) is the first approved biosimilar to tocilizumab (Actemra; Genentech) as both intravenous and subcutaneous.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Specialty Pharmacy Services Produce Better Health Outcomes for RA Patients
November 28th 2012In a retrospective analysis, researchers concluded that rheumatoid arthritis patients had better outcomes when they filled their prescriptions through a mail-order specialty pharmacy rather than a retail pharmacy.
Read More
Xeljanz: Juggling a Delicate Risk-Benefit Ratio
November 16th 2012Pfizer's Xeljanz (tofacitinib) is the first Janus kinase inhibitor approved for rheumatoid arthritis and the first oral biologic within the RA class. Dina Rufo of GlobalData discusses the factors that will affect uptake of the drug.
Read More
FDA Approves Expanded Indication for Actemra in Rheumatoid Arthritis
October 12th 2012Genentech, Inc, a member of the Roche Group, today announced that the FDA has expanded the approved indication for Actemra (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).
Read More
Phase 3 study findings showed that patients with active moderate to severe rheumatoid arthritis (RA) who received an investigational intravenous (IV) formulation of the anti-tumor necrosis factor (TNF)-alpha therapy Simponi (golimumab) demonstrated significant improvements in signs, symptoms, and disease activity.
Read More